Rabbit Anti-Aurora B [EP136]: RM0005, RM0005RTU7

Intended Use: For Research Use Only

Description: The serine/threonine protein kinase aurora B (Aurora B) is a chromosomal passenger protein critical for accurate chromosome segregation, cytokinesis, protein localization to the centromere and kinetochore, correct microtubule-kinetochore attachment, and regulation of the mitotic checkpoint. Aurora B forms a tight complex with inner centrosome protein and survivin Inactivation of any of these proteins causes similar defects in chromosome segregation. A significant overexpression of Aurora B has been found in a variety of human tumors including non-small cell lung carcinoma, astrocytoma, seminoma and carcinomas of the colon, prostate, endometrium and thyroid. The expression level of Aurora B is associated with cell proliferation and prognosis in these tumors.

Specifications:

Clone:	EP136
Source:	Rabbit
Isotype:	IgG
Reactivity:	Human
Localization:	Nucleus
Formulation:	Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC

Package:

Description	Catalog No.	Size
Aurora B Concentrated	RM0005	1 ml
Aurora B Prediluted	RM0005RTU7	7 ml

IHC Procedure*:

Positive Control Tissue:	Tonsil, colon cancer
Concentrated Dilution:	10-30
Pretreatment:	EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human colon cancer stained with anti-Aurora B using DAB

References:

1. Quantitative Proteomics Reveals That the Inhibition of Na(+)/K(+)-ATPase Activity Affects S-Phase Progression Leading to a Chromosome Segregation Disorder by Attenuating the Aurora A Function in Hepatocellular Carcinoma Cells. Xu Z, et al. J Proteome Res 14:4594-602, 2015.
2. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection. Behnsawy HM, et al. Urol Oncol 29:495-501, 2011.
3. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Fiskus W, et al. Clin Cancer Res 14:6106-15, 2008.

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 510-509-3153 www.medaysis.com